BSECompany Update1 Nov 2026 · 1 Nov 2026, 07:07 pm
Press Release
Shree Ganesh Remedies Ltd · 540737
✦ AI SummaryResults
Shree Ganesh Remedies Limited reported its Q2 and H1FY27 financial results, with revenue from operations decreasing by 23% YoY and 54% YoY, respectively. EBITDA margins also decreased by 1,483 bps YoY and 1,141 bps YoY, respectively. The company's management expressed confidence in the core business recovering to its earlier levels over the next few quarters, driven by improved traction from European customers and the domestic market.
Analysis Scores
Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk8/10
Liquidity Impact4/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Shree Ganesh Remedies Ltd - 540737 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Attachments (1)
📄pdf
Download →
bebb5652-ad21-4b31-a0ed-9b9fdf02a813.pdf
View document text
November 01, 2026
The BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip Code: 540737
Dear Sir/Ma’am,
Sub: Press Release
With reference to the captioned subject, we enclose herewith the Press Release with respect
to Unaudited Financial Results of the Company for the quarter and half year ended
September 30, 2026.
Kindly take the same on your record.
Thanking You,
Yours faithfully,
For Shree Ganesh Remedies Limited
Akanksha
Company Secretary and Compliance Officer
Enc. a/a
SHREE GANESH REMEDIES LIMITED REPORTS Q2 & H1FY27 RESULTS
Ankleshwar, October 31st, 2026: Shree Ganesh Remedies Limited, one of the fastest
growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals,
announced its financial results for Q2 & H1FY27.
Financial Highlights for Quarter Ended September 30th, 2026:
(₹ In crore & %)
REVENUE EBITDA PAT EBITDA MARGINS
23.29 Cr. 3.94 Cr. 1.63 Cr. 16.9%
-23% YoY -59% YoY -67% YoY -1,483 BPS YoY
13.61 Cr. 9.37 Cr. 11.71 Cr. 11.28 Cr.
Revenue from Pharma Revenue from Revenue from Revenue from
Intermediates in Q2FY27 Speciality Chemicals Exports in Q2FY27 Domestic Sales
in Q2FY27 in Q2FY27
Financial Highlights for Half Year Ended September 30th, 2026:
(₹ In crore & %)
REVENUE EBITDA PAT EBITDA MARGINS
37.65 Cr. 7.29 Cr. 2.75 Cr. 19.4%
-32% YoY -57% YoY -67% YoY -1,141 BPS YoY
25.10 Cr. 12.25 Cr. 20.35 Cr. 17.00 Cr.
Revenue from Pharma Revenue from Revenue from Revenue from
Intermediates in H1FY27 Speciality Chemicals Exports in H1FY27 Domestic Sales
in H1FY27 in H1FY27
Commenting on the results, Mr. Gunjan Kothia, Promoter said:
FY27 began on a challenging note for the Company. Subdued demand from Europe and a
difficult operating environment weighed on our first-quarter performance. Over the past three
months, we have worked steadily through these challenges, and this is reflected in an improved
performance in Q2FY27.
Much of this improvement has come from our core pharmaceutical intermediates business,
where we sharpened our focus on the domestic market to make up for softer exports. Alongside
this, we have begun to see improved traction from our European customers, which gives us
confidence that the core business will recover to its earlier levels over the next few quarters. We
have also broadened our portfolio during the quarter by commencing commercial production
of two new pharmaceutical intermediates, one for anti-diabetic and one for cardiovascular
applications. Both have received an encouraging response in the domestic market, and we plan
to take them to export markets in the coming quarters.
While volumes are on the path to recovery, they remain below earlier levels, and this has put
some pressure on our margins. Raw material prices added to this pressure, rising significantly
and staying volatile through the quarter. We expect input costs to ease as geopolitical
conditions stabilise, and margins to normalise as our sales return to earlier levels. Throughout,
we remain focused on healthy profitability, including on the new products we are developing.
As we work towards this recovery, we continue to build the businesses that will drive our next
phase of growth. Our CRAMS business has made strong progress during the quarter. On our
specialty chemicals project for South-East Asian markets, we have successfully completed the
pilot trials, and the batches are now undergoing stability testing, with commercial supplies
expected from Q1FY28. A second specialty chemicals product for the same region has cleared
laboratory trials and moved to the pilot stage. In Europe, we are making positive progress on
two molecules for pharmaceutical and agrochemical applications. To support this pipeline,
construction of Block 7A is now complete and trials have begun.
This year has brought its own set of challenges, and we have responded by strengthening our
domestic presence, adding to our product portfolio and advancing our CRAMS pipeline. With
the core business recovering, new products gaining traction and new capacity coming online,
we look forward to a stronger performance in the periods ahead.
Financial Highlights:
PARTICULARS YoY QoQ YoY
Q2FY26 Q1FY27 Q2FY27 H1FY26 H1FY27
(₹ IN CRORES) Change Change Change
Revenue from Operations 30.32 14.36 23.29 -23% 62% 54.98 37.65 -32%
Total Income 31.00 15.30 24.70 -20% 61% 56.33 40.00 -29%
Operating Expenses 20.70 11.01 19.36 -6% 76% 38.07 30.37 -20%
EBITDA (Excluding OI & EI) 9.62 3.35 3.94 -59% 17% 16.92 7.29 -57%
-1,483 -644 -1141
EBITDA % 31.7% 23.3% 16.9% 30.8% 19.4%
bps bps bps
Finance Cost 1.01 0.32 0.58 -43% 80% 1.95 0.89 -54%
Depreciation & Ammortization 2.59 2.44 2.50 -3% 3% 5.01 4.94 -1%
PBT 6.71 1.53 2.26 -66% 48% 11.31 3.79 -66%
PAT 4.96 1.12 1.63 -67% 46% 8.41 2.75 -67%
EPS (₹) 3.86 0.87 1.28 -67% 47% 6.55 2.15 -67%
About Shree Ganesh Remedies Limited: (SGRL)
Shree Ganesh Remedies Limited is a leading player in the chemical manufacturing industry, specialising in
pharmaceutical intermediates and specialty chemicals. With over 20 years of excellence, the company is
renowned for its unparalleled expertise in advanced chemical synthesis and complex chemical reactions.
Strategically expanding its operations, Shree Ganesh Remedies is focused on innovation through strategic
R&D investments and state-of-the-art infrastructure. The company serves over 20 countries, including key
markets in the EU and the US, offering tailored solutions to global industry leaders. Committed to sustainable
practices, Shree Ganesh Remedies holds multiple accreditations, including ISO certifications and EcoVadis
Bronze. With ongoing expansions at its Ankleshwar and Dahej sites and a strategic shift towards complex niche
specialty chemicals, the company is well-positioned for future growth and continues to deliver high-quality,
custom manufacturing solutions to its clients.
Contact us:
Akanksha Choudhary Abhishek Mehra
Company Secretary Investor Relations Advisors
Shree Ganesh Remedies Limited TIL Advisors Private Limited
Email: investors@ganeshremedies.com Email: abhishek@theinvestmentlab.in
Mobile No.: +91 95588 14500
Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to
certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that
could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Shree Ganesh Remedies Limited
will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-
looking statements to reflect subsequent events or circumstances.